Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
3(50%)
Results Posted
100%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
3
50%
Ph phase_1
1
17%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Recruiting2
Active, not recruiting1
unknown1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 31 (16.7%)
N/A1 (16.7%)

Trials by Status

active_not_recruiting117%
unknown117%
recruiting233%
completed117%
terminated117%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_2

Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

NCT07747740
recruitingnot_applicable

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

NCT07466238
active_not_recruitingphase_2

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

NCT07480850
terminatedphase_1

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

NCT05494866
completedphase_3

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

NCT00446225
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07747740Phase 2

Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Recruiting
NCT07466238Not Applicable

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Recruiting
NCT07480850Phase 2

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Active Not Recruiting
NCT05494866Phase 1

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Terminated
NCT00446225Phase 3

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Completed
NCT04405375Phase 2

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6